NOX4 modulates breast cancer progression through cancer cell metabolic reprogramming and CD8+ T cell antitumor activity
These findings show that NOX4 constrains breast cancer aggressiveness by limiting MYC-driven metabolic adaptations and supporting CD8+ T cell-mediated immunity. Loss of NOX4 promotes a more malignant phenotype and dampens T cell responses, whereas its overexpression prolongs survival and enhances checkpoint inhibitor efficacy. Therapeutically targeting the NOX4-MYC axis and leveraging NOX4's immunomodulatory capacity could offer promising strategies for breast cancer management.
Authors
- Xiaopeng Jing
- Shan Zhu (ORCID: https://orcid.org/0000-0002-8710-7913)
- Rui Sun (ORCID: https://orcid.org/0000-0002-0390-0958)
- Chao Luo (ORCID: https://orcid.org/0000-0002-7127-3861)
- Wei Gong (ORCID: https://orcid.org/0000-0002-9949-6207)
- Min Peng (ORCID: https://orcid.org/0000-0003-0422-0265)
- Yongfu Xiong (ORCID: https://orcid.org/0000-0001-9016-8509)
- Jia Feng
- Jian Qin
- Yiming Weng
Institutions
- Xuzhou Medical College (CN)
- Wuhan University (CN)
- Wuhan Puai Hospital (CN)
- Huaian First People’s Hospital (CN)
- Hubei University of Arts and Science (CN)
- Second People’s Hospital of Huai’an (CN)
- Renmin Hospital of Wuhan University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-07
- DOI
- https://doi.org/10.3389/fimmu.2025.1534936
- Citations
- 3
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.39
Funders
- National Natural Science Foundation of China
- Wuhan University
- Renmin Hospital of Wuhan University